For the roughly one in three adults with chronic kidney disease who also carry elevated cardiovascular risk, the therapeutic toolkit has historically been limited to renin-angiotensin blockade and, more recently, SGLT2 inhibitors. Finerenone's emergence as a non-steroidal mineralocorticoid receptor antagonist represents a mechanistically distinct addition that may address residual cardiorenal risk not captured by existing agents — and this narrative review synthesizes why that distinction matters clinically.
At the molecular level, mineralocorticoid receptor overactivation drives a triad of inflammation, oxidative stress, and fibrosis in both cardiac and renal tissue — largely independent of blood pressure. Finerenone differs from older steroidal antagonists such as spironolactone and eplerenone through greater receptor selectivity, more balanced distribution across cardiac and renal compartments, and differential cofactor recruitment that shifts the receptor toward anti-inflammatory rather than merely diuretic signaling. The FIDELIO-DKD and FIGARO-DKD trials — each enrolling thousands of patients with type 2 diabetes and CKD — documented statistically significant reductions in kidney disease progression and major adverse cardiovascular events. The pooled FIDELITY analysis reinforced consistency across the glycemic and renal-function spectrum. The FINEARTS-HF trial then extended benefit to heart failure with preserved or mildly reduced ejection fraction, independent of diabetic status — a clinically important expansion given that HFpEF remains treatment-resistant by most standards.
Several contextual points deserve emphasis. First, this is a narrative rather than systematic review, meaning selection bias in included evidence cannot be excluded. Second, the hyperkalemia signal — the primary safety concern with any MR antagonist — appeared manageable under structured monitoring, but real-world adherence to such protocols is rarely as rigorous. Third, preliminary signals around retinal and hepatic outcomes, while intriguing, remain hypothesis-generating. The review is best read as a coherent mechanistic framing of an already-approved drug rather than new evidence per se — consolidating rather than advancing the field.